| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | Docket No. 3829.04 |
|---|---|

In Re Application Of: **WECHTER, ET AL.**



| Serial No. | Filing Date | Examiner | Group Art Unit |
|---|---|---|---|
| 10/762,681 | JANUARY 21, 2004 | N/A | N/A |

Title: **THERAPEUTICALLY ACTIVE COMPOUNDS**

Address to:
**Commissioner for Patents**
**P.O. Box 1450**
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

   ☐ the statement specified in 37 CFR 1.97(e);

   **OR**

   ☐ the fee set forth in 37 CFR 1.17(p).

| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | Docket No. 3829.04 |
|---|---|

In Re Application: **WECHTER, ET AL.**



| Serial No. | Filing Date | Examiner | Group Art Unit |
|---|---|---|---|
| 10/762,681 | JANUARY 21, 2004 | N/A | N/A |

**THERAPEUTICALLY ACTIVE COMPOUNDS**

## Payment of Fee

**(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))**

☐ A check in the amount of is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. **16-1331** as described below.

- ☐ Charge the amount of
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

_____
(Date)

*Signature*

*Typed or Printed Name of Person Signing Certificate*

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on **APRIL 28, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Signature of Person Mailing Correspondence*

MELINDA A. TOMPKINS

*Typed or Printed Name of Person Mailing Certificate*

***This certificate may only be used if paying by deposit account.**

*Signature*

Dated: **APRIL 28, 2004**

**HANA VERNY (REG. NO. 30,518)**
**PETERS, VERNY, JONES & SCHMITT, L.L.P.**
**425 SHERMAN AVENUE, SUITE 230**
**PALO ALTO, CA 94306**
**TELEPHONE: (650)324-1677**
**FACSIMILE: (650)324-1678**

cc:

FOR PTO-1449 (Modified)

# LIST OF PATENTS AND PUBLICATIONS FOR APPLICANTS INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



| ATTY. DOCKET NO. | SERIAL NO. |
|---|---|
| 3829.04 | 10/762,681 |
| APPLICANT : WECHTER, ET AL. | |
| FILING DATE : JANUARY 21, 2004 | GROUP N/A |

REFERENCE DESIGNATION — U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|---|---|
| | | | | US | | | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|---|---|---|---|
| | A | | Stokke, O., et al. Biochim. Biophys. Acta **144**, 271-84 (1967) α-Oxidation as an alternative pathway for the degradation of Branched-Chain Fatty acids in man and its failure in Patients with Refsum's diasease |
| | B | | Steinberg, D., et al. J. Lipid Res. **7**, 684-91 (1966) Effects of dietary phytol and phytanic acid in animals |
| | C | | McCarty, M.F. Med. Hypothesis **56**, 217-19 (2001) The chlorophyll metabolite phytanic acid is a natural rexinoid - potential for treatment and prevention of diabetes |
| | D | | Verhoeven, N.M., et al. Eur. J. Pediatr. **156**, S83-87 (1997) Stable isotope studies of phytanic acid α-Oxidation: in vivo production of formic acid |
| | E | | Mize, C.E., et al. Biochim. Biophys. Acta **176**, 720-39 (1969) A major pathway for the mammalian oxidative degradation of phytanic acid |
| | F | | Baxter, J.H. J. Lipid Res. **9**, 636-641 (1968) Absorption of chlorophyll phytol in normal man and in patients with Refsum's disease |
| | G | | Wierzbicki, A.S., et al. J. Lipid Res. 44, 148-188 (2003) Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease |
| | H | | Wanders, R.J.A., et al. Biochim. Biophys. Acta **1631**, 119-135 (2003) Phytanic acid α-Oxidation, new insights into an old problem: a review |
| | I | | Ferdinandusse, S., et al. J. Lipid Res. **43**, 438-444 (2002) Stereochemistry of the peroxisomal branched-chain fatty acid α- and β-oxidation systems in patients suffering from different peroxisomal disorders |
| | J | | Verhoeven, N.M. et al. J. Lipid Res. **39**, 66-74 (1998) Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts |
| | K | | Van Veldhoven P.P., et al. Biochem. Soc. Transac. 29, 292-98 (2001) Further insights into peroxisomal lipid breakdown via α- and β-oxidation |
| | L | | Verhoeven, N.M. and Jakobs, C. Prog. Lipid Res. **40**, 453-466 (2001 Human Metabolism of phytanic acid and pristanic acid |
| | M | | Schluter, A., et al. FEBS Lett. **517**, 83-6 (2002) Phytanic acid, but not pristanic acid mediates the positive effects of phytol derivatives on brown adipocyte differentiation |
| | N | | Schluter, A., et al. Biochem. J. **362**, 61-69 (2002) Phytanic acid, a novel activator of uncoupling protein-1 gene transcription and brown adipocyte differentiation |
| | O | | Verhoeven, N.M. et al. J. Lipid Res. **40**, 260-6 (1999) Analysis of pristanic acid β-oxidation intermediates in plasma from healthy controls and patients affected with peroxisomal disorders by stable isotope dilution gas chromatography mass spectrometry |
| | P | | Tserng, K.-Y., et al. J. Lipid Res. **31**, 763-771 (1990) Abnormal urinary excretion of unsaturated dicarboxylic acids in patients with medium-chain acyl-CoA dehydrogenase deficiency |
| | Q | | Jin, S.-J. and Tserng, K.-Y. J. Lipid Res. **30**, 1611-1619 (1989) Identification of isomeric unsaturated medium-chain dicarboxylic acids in human urine |
| | R | | Stellaard, F., et al. Clinica Chimica Acta **192**, 133-144 (1990) Stable isotope dilution analysis of very long chain fatty acids in plasma, urine and amniotic fluid by electron capture negative ion mass fragmentography |
| | S | | ten Brink, H.J., et al. J. Lipid Res. **33**, 41-7 (1992) Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography |
| | T | | Zhou, Y.-T., et al. Proc. Natl. Acad. Sci. USA **96**, 23941-2395 (1999) Reversing adipocyte differentiation: Implications for treatment of obesity |

| | | | |
|---|---|---|---|
| | U | | Young, S.P., et al. Clinical Science **101**, 697-705 (2001) Effects of phytanic acid on the vitamin E status, lipid composition, and physical properties of retinal cell membranes: implications for adult Refsum disease |
| | V | | Zomer, A.W.M., et al., J. Lipid Res. **41**, 1801-7 (2000) Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor α |
| | W | | Kase, B.F., et al. Anal. Biochem. **196**, 95-8 (1991) Separation of phytanic and pristanic acid by high-pressure liquid chromatography: application of the method |
| | X | | Schluter, A., et al., Internatl. J. Obesity **26**, 1277-1280 (2002) The chlorophyll-derived metabolite phytanic acid induces white adipocyte differentiation |
| | Y | | Gibbons, G.F. Prog. Lipid Res. **42**, 479-497 (2003) Regulation of fatty acid and cholesterol synthesis: co-operation or competition? |
| | Z | | Rontani, J.-F., et al. Appl. Environ. Microb. **65**, 5484-5492 (1999) Biodegradation of free phytol by bacterial communities isolated from marine sediments under aerobic and denitrifying conditions |
| | AA | | Paton, B.C., et al. J. Clin. Invest. **97**, 681-688 (1996) Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal β-oxidation effects |
| | BB | | Jin, S.-J., et al. J. Biol. Chem **267**, 119-125 (1992) Incomplete fatty acid oxidation, the production and epimerization of 3-hydroxy fatty acids |
| | CC | | Liebich, H.M., et al. J. Chromatog. **199**, 181-189 (1980) Gas chromatography-mass spectrometry of saturated and unsaturated dicarboxylic acids in urine |
| | DD | | Vreken, P., et al. J. Chromatog. B **713**, 281-7 (1998) Rapid stable isotope dilution analysis of very-long-chain fatty acids, pristanic acid and phytanic acid using gas chromatography-electron impact mass spectrometry |
| | EE | | Croes, K., et al. J. Lipid Res. **40**, 601-6 (1999) Stereochemistry of the α-oxidationof 3-methyl-branched fatty acid in rat liver |
| | FF | | Croes, K., et al Eur. J. Biochem. **240**, 674-683 (1996) α-oxidation of 3-methyl-substituted fatty acid in rat liver, production of formic acid instead of $CO_2$, cofactor requirements subcellular localization and formation of a 2-hydroxy-3-methylacyl-CoA intermediate |
| | GG | | Vanhove, G., et al. J. Biol. Chem. **266**, 24670-5 (1991) Mitochondrial and peroxisomal β oxidation of the branched chain fatty acid 2-methylpalmitate in rat liver |
| | HH | | Foulon, V., et al. Proc. Natl. Acad. Sci. USA **96**, 10039-10044 (1999) Purification, molecular cloning and expression of 2-hydroxyphytanoyl-CoA lyase, a peroxisomal thiamine pyrophosphate-dependent enzyme that catalyzes the carbon-carbon bond cleavage during α-oxidation of 3-methyl-branched fatty acids |
| | II | | Amery, L. et al. J. Lipid Res. **41**, 1752-59 (2000) Mitochondrial and peroxisomal targeting of 2-methyl-CoA racemase in humans |
| | JJ | | Kotti, T.J., et al. J. Biol. Chem. **275**, 20887-95 (2000) In mouse α-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes |
| | KK | | Mukherji, M., et al. Prog. J. Lipid Res. **42**, 359-76 (2003) The chemical biology of branched-chain lipid metabolism |
| | LL | | Shieh, W.-R. And ChenC.-S. J. Biol. Chem. **258**, 3487-93 (1993) Purification and characterization of novel "2-arylpropionyl-CoA epimerases" from rat liver cytosol and mitochondria |
| | MM | | Reichel, C., et al. J. Pharmac. and Exptl. Therapeutics **51**, 576-82 (1997) Molecular cloning and expression of a 2-arylpropionyl-Coezyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen |
| | NN | | Reichel, C., et al. Biochem. Pharmacol. **50**, 1803-6 (1995) 2-arylpropionyl-CoA epimerases: partial pepetide sequence and tissue localization |
| | OO | | Ferdinandusse, S., et al. J. Lipid Res. **41**, 1890-96 (2000) Subcellular localization and physiological role of α-methylacyl-CoA racemase |
| | PP | | Steinberg, D., et al. Biochem. Biophys. Res. Comm. **19**, 783-789 (1965) Conversion of U-$C^{14}$-Phytol to phytanic acid and its oxidation in Heredopathia atactica polyneuritiformis |
| | QQ | | Hansen, R.P., et al. Biochim. Biophys Acta **116**, 178-80 (1966) The fate of phytanic acid when administered to rats |
| | RR | | Avigan, J. Biochim. Biophys Acta **116**, 391-4 (1966) The presence of phytanic acid in normal human and animal plasma |
| | SS | | Mize, C.E., et al. J. Lipid Res. **7**, 692-697 (1966) Metabolism of phytol U-$^{14}$C and phytanic acid-U-$^{14}$C in the rat |
| | TT | | Avigan, J., et al. Biochim. Biophys Res. Comm. **24**, 838-844 (1966) Alpha -decarbonxylation, an important pathway for degradation of phytanic acid in animals |
| | UU | | Avigan, J. Biochim. Biophys Acta **125**, 607-10 (1966) Pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) and phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) content of human and animal tissues |
| | VV | | Mize, C.E., et al. Biochem. Biophys. Res. Comm. **25**, 359-365 (1966) A pathway for oxidative degradation of phytanic acid in mammals |
| | WW | | Baxter, J.H. and Steinberg, D. J. Lipid Res. **8**, 615-20 (1967) Absorption of phytol from dietary chlorophyll in the rat |
| | XX | | Baxter, J.H. and Steinberg, D. J. Lipid Res. **9**, 636-41 (1968) Absorption of chlorophyll phytol in nomral man and in patients with Refsum's disease |

| | | | |
|---|---|---|---|
| | YY | | Baxter, J.H. and Milne, G.W.A. Biochim. Biophys. Acta. **176**, 265-77 (1969) Phytenic acid: identification of five isomers in chemical and biological products of phytol |
| | ZZ | | Jansen, G.A. et al. Biochem. Biophys. Res. Comm. **283**, 674-9 (2001) Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid α-oxidation pathway is localized in peroxisomes |
| | AAA | | Ferdinanadusse, Ss., et al. 2-methyl branched-chain fatty acid β-oxidation in peroxisomes and mitochondria and the role of 2-methylacyl-CoA racemase therein. In New Avenues of Research in Fatty Acid Oxidation and Ketone Body Metabolism, Eaton and Quant Ed FAOKX Press, London 2001 |
| | BBB | | Vanhooren, J.C.T., et al. Int. J. Biochem. **26**, 1095-1101 (1994) Activation of 3-methyl-branched fatty acids in rat liver |
| | CCC | | Van Veldhoven, P.P. et al. FEBS Lett. **388**, 80-84 (1996) Peroxisomal β-oxidation of 2-methyl-branched acyl-CoA esters: stereospecific recognition of the 2S-methyl compounds by trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase |
| | DDD | | Dieuadie-Noubhani, M., et al. Biochem. J. 325, 367-73 (1997) Evidence that multifunctional protein 2, and not multifunctional protein 1, is involved in the peroxisomal β-oxidation of pristanic acid |
| | EEE | | Ackman, R.G., et al. Lipids **2**, 357-362 (1967) The occurance of diastereomers of phytanic and pristanic acids and their determination by gas-liquid chromatography |
| | FFF | | Dhopeshwarkar, G.A. Prog. Lipid Res. **19**, 107-118 (1981) Naturally occurring food toxicants: toxic lipids |
| | GGG | | Stokke O., et al. Scand. J. Clin. Lab. Invest. **46**, 3-10 (1986) Disorders related to the metabolism of phytanic acid |
| | HHH | | van den Branden, C., et al. Pediat. Res. **20**, 411-15 (1986) Phytol and peroxisome proliferation |
| | III | | Vallance, H. and Applegarth, D. Clin. Biochem. **27**, 183-6 (1994) An improved method for quantification of very long chain fatty acids in plasma |
| | JJJ | | Schmitz, W., et al. Eur. J. Biochem. **222**, 313-323 (1994) Purification and properties of an α-methlacyl-CoA racemase from rat liver |
| | KKK | | Pahan, K. and Singh, I. J. Lipid Res. **36**, 986-997 (1995) Phytanic acid oxidation: topographical localization of phytanoyl-CoA ligase and transport of phytanic acid in human peroxisomes |
| | LLL | | Mihalik, S.J., et al. Eur. J. Biochem. **232**, 545-551 (1995) Phytanic acid α-oxidation in rat liver peroxisomes |
| | MMM | | Watkins, P.A., et al. J. Lipid Res. **37**, 2288-2295 (1996) Phytanic acid activation in rat liver peroxisomes is catalyzed by long-chain acyl-CoA synthetase |
| | NNN | | Schmitz, W. and Conzelmann, E. Eur. J. Biochem. **244**, 434-440 (1997) Stereochemistry of peroxisomal and mitochondrial β-oxidation of α-methylacyl-CoAs |
| | OOO | | Clayton, P.T. Biochem. Soc. Trans. **29**, 298-305 (2001) Clinical consequences of deffects in peroxisomal β-oxidation |
| | PPP | | Little, J.M. et al. Drug Metab. Dispos. **30**, 551-553 (2002) Glucoronidation of the dietary fatty acids, phytanic acid and docosahexaenoic acid, by human UDP-glucoronosyltransferases |
| | QQQ | | Heim, M. et al. FASEB J. **16**, 718-720 (2002) Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes |
| | RRR | | Browne, G.S., et al. Biochem. Pharmacol. **57**, 837-44 (1999) Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β-oxidation and oxidative phosphorylation by the non-steroidal inflammatory drugs ibuprofen, flurbiprofen and ketorolac |
| | SSS | | Dacremont, G., et al. J. Inher. Metab. Dis. **18**, 76-83 (1995) Measurement of very long-chain fatty acids, phytanic and pristanic acid in plasma and cultured fibroblasts by gas chromatography |
| | TTT | | Rezanka, T. and Votruba, J. Anal. Chim. Acta **465**, 273-297 (2002) Chromatography of very long-chain fatty acids from animal and plant kingdoms |
| | UUU | | Egge, H., et al. FEBS Lett. **2**, 255-8 (1969) Minor constituents of human milk (I) identification of cyclohexaneundecanoic acid and phytanic acid in human milk fat by a combination gas chromatograph-mass spectrometer |
| | VVV | | Lough, A.K. Lipids **12**, 115-9 (1976) The phytanic acid content of the lipids of bovine tissues and milk |
| | WWW | | Verhoeven, N.M., et al. Biochem. Biophys. Res. Comm. **237**, 33-36 (1997) Resolution of the phytanic acid α-oxidation pathway: identification of pristanal as the product of the decarboxylation of 2-hydroxyphytanoyl-CoA |
| | XXX | | Brown, W.G. Org. React. **6**, 469-509 (1951) Reductions by lithium aluminum hydride |
| | | | |
| | | | |
| | | | |

| | |
|---|---|
| **EXAMINER** | **DATE CONSIDERED** |

| EXAMINER: | Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |
|---|---|